KNOXVILLE - Provectus Biopharmaceuticals, Inc. ('Provectus' or the 'Company') (OTCQB: PVCT) today announced that data from ongoing preclinical research on the topical administration of a formulation of Provectus's proprietary, pharmaceutical-grade, small molecule, rose bengal sodium ('RBS') drug substance are being presented at the annual meeting of the Society for Investigative Dermatology ('SID'), to be held May 15-18, 2024 in Dallas, Texas.

The accepted SID abstract is titled 'Assessing the safety and toxicity of multi-dosed topical Rose Bengal Sodium (RBS) in a murine model of full-thickness cutaneous injury' (Control ID 4074036, Final ID 813, Current Category: Translational Studies and Early Preclinical to Clinical).

The work underlying this poster presentation is part of an ongoing sponsored research program with Amina El Ayadi, Ph.D., Assistant Professor, Division of Surgical Sciences, Department of Surgery at the University of Texas Medical Branch at Galveston to characterize the effects of RBS on full-thickness cutaneous wounds and during the subsequent phases of wound healing.

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus's lead HX molecule is named rose bengal sodium.

Provectus's medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.

FORWARD-LOOKING STATEMENTS

The information in this press release may include 'forward-looking statements,' within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as 'seek,' 'anticipate,' 'budget,' 'plan,' 'continue,' 'estimate,' 'expect,' 'forecast,' 'may,' 'will,' 'project,' 'predict,' 'potential,' 'targeting,' 'intend,' 'could,' 'might,' 'should,' 'believe,' and similar words suggesting future outcomes or statements regarding an outlook.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.

Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.

Risks, uncertainties, and assumptions include those discussed in the Company's filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of: the Company's Annual Report on Form 10-K for the year ended December 31, 2022. And Provectus' Quarterly Report on Form 10-Q for the period ended September 30, 2023.

Contact:

Heather Raines

Tel: 866-594-5999

(C) 2024 Electronic News Publishing, source ENP Newswire